Updated on 19 October, 2021
The Thc Test is the only approved non-invasive and non-toxic clinical tool to measure THMs in a patient's bloodstream. The test is performed on an individual basis according to specific instructions from the laboratory. The test is completed within three days of the last possible exposure, so it is important to submit the completed blood sample on the date that has been scheduled for the procedure.
To begin, an accredited laboratory will collect urine samples that are collected at home. A special urinalysis kit is then used to identify the species of the bacteria that are currently present in the patient's blood. After this has been completed, the technician will collect the urine samples in a clean, sterile cup from the area in which the patient has opted to take the sample. An Accupinch THC Assay kit is used to generate a cross-reactive bead by exposing the urine sample to an activated form of Thc.
The primary objective of the Accupinch THC Assay is to confirmatory testing for total cellular count (TFC), chemiluminescent assay (CGA) and fluorescence. T FC is a highly sensitive test that is used to measure the amount of THMs present in a patient's blood stream. CGA is an HIV test that measures the presence of four specific colors - eu, euw, ecu and fi - in urine samples taken from patients with known HIV infections. Fluorescent analysis is performed to confirm positive results for the detection of any color-based compounds. The entire procedure is completed within ten minutes or less after collection.
In order to generate cross-reactive bead by using THMs, an THM-detecting assay is also used. The specific sensitivity of this particular assay has been validated in clinical studies. The result is a high level of cross-reactivity in the overall samples of patients with known HIV infection. Therefore, these assays can be considered as more efficient than the commonly used cadaver-based cross-reactivity assays, such as the Assay for Therapeutic Purification (ATP).
The primary objective of the Thc Test is to determine whether it is possible to conclusively identify the primary drug source of each sample. If a positive identification is achieved, then the specimen is sent for confirmatory testing using the cadaver-based Assays for Sequencing of Antigens (ASA). These two primary assays have been established to be highly reliable and accurate in the evaluation of human plasma samples from HIV-infected patients.
In addition to these primary antibodies, a wide range of secondary antigens and fluorescent probes have been developed by various laboratories in response to the need for improved sensitivity and accuracy of the Thc Test. Because of this, the Thc test has evolved over the years to include a variety of assays that can specifically detect at least one or more of the primary antibodies. Depending on the type of primary antibody used, different Thc tests may also give results indicating that a specific strain of HIV is present in the patient's plasma. The primary and multiple immunosuppressive actions of CBD and its derivatives have been proposed to offer a mechanism of action through which the virus invades the T-cells. Therefore, some laboratories combine diagnostic Thc assays with urine drug screening assays in order to determine the presence of a single pharmacological agent, such as CBD.
While the precise mechanism by which CBD induces cross-reactivity in cells is not known, several biologically active plant compounds includingTHC and dimethylaminoethanol (DMAE) have been found to interact with and possibly compete with HIV antigens and T-cells. DMAE has been found to cause an impairment of HIV-associated regulation of the inflammatory response in human lymphoid cells and may cause suppression of T-cell receptor and interferon activity. Similarly, several reports of the clinical effects of DMAE on patients with essential thymic dysfunction and other life-threatening diseases have been conflicting. While some studies suggest that DMAE affects HIV-related outcomes in patients with HIV and some other virus-infected individuals, others report no effects or minimal adverse effects of DMAE on patients' health.
Because the primary purpose of the Thc test is to detect any evidence of cross-reactivity, many laboratories prefer to perform a secondary test called ELISA. An ELISA test for CBD allows for more sensitive detection of the immunogenicity of this compound in various types of cells. While the sensitivity of the secondary test for CBD is lower than that of the primary test, it is generally considered less reliable because of the difficulty of detecting subtle differences in the concentrations of CBD across different types of cells. Nonetheless, it may be useful in the diagnosis of certain patients with CBD-induced cross-reactivity who may not respond to the primary therapy.